Epigenetic silencing of GDF1 disrupts SMAD signaling to reinforce gastric cancer development

Subjects

Abstract

Accumulating evidence reveals the effectiveness of epigenetic therapy in gastric cancer. However, the molecular mechanisms and targets underlying such therapeutic responses remain elusive. Herein, we report an aberrant yet therapeutically rectifiable epigenetic signaling in gastric carcinogenesis. Administration of DNA-demethylating drug 5-aza-2′-deoxycytidine (5-aza-dC) reduced gastric cancer incidence by ~74% (P<0.05) in N-nitroso-N-methylurea-treated mice. Through genome-wide methylation scanning, novel promoter hypermethylation-silenced and drug-targeted genes were identified in the resected murine stomach tumors and tissues. We uncovered that growth/differentiation factor 1 (Gdf1), a member of the transforming growth factor-β superfamily, was silenced by promoter hypermethylation in control tumor-bearing mice, but became reactivated in 5-aza-dC-treated mice (P<0.05). In parallel, the downregulated SMAD2/3 phosphorylation in gastric cancer was revived by 5-aza-dC in vivo. Such hypermethylation-dependent silencing and 5-aza-dC-mediated reactivation of GDF1-SMAD2/3 activity was conserved in human gastric cancer cells (P<0.05). Subsequent functional characterization further revealed the antiproliferative activity of GDF1, which was exerted through activation of SMAD2/3/4-mediated signaling, transcriptional controls on p15, p21 and c-Myc cell-cycle regulators and phosphorylation of retinoblastoma protein. Clinically, hypermethylation and loss of GDF1 was significantly associated with reduced phosphorylated-SMAD2/3 and poor survival in stomach cancer patients (P<0.05). Taken together, we demonstrated a causal relationship between DNA methylation and a tumor-suppressive pathway in gastric cancer. Epigenetic silencing of GDF1 abrogates the growth-inhibitory SMAD signaling and renders proliferation advantage to gastric epithelial cells during carcinogenesis. This study lends support to epigenetic therapy for gastric cancer chemoprevention and identifies a potential biomarker for prognosis.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

References

  1. 1

    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90.

  2. 2

    Crew KD, Neugut AI . Epidemiology of gastric cancer. World J Gastroenterol 2006; 12: 354–362.

  3. 3

    Yoda Y, Takeshima H, Niwa T, Kim JG, Ando T, Kushima R et al. Integrated analysis of cancer-related pathways affected by genetic and epigenetic alterations in gastric cancer. Gastric Cancer 2015; 18: 65–76.

  4. 4

    Rodriguez-Paredes M, Esteller M . Cancer epigenetics reaches mainstream oncology. Nat Med 2011; 17: 330–339.

  5. 5

    Zouridis H, Deng N, Ivanova T, Zhu Y, Wong B, Huang D et al. Methylation subtypes and large-scale epigenetic alterations in gastric cancer. Sci Transl Med 2012; 4: 156ra140.

  6. 6

    Wang K, Yuen ST, Xu J, Lee SP, Yan HH, Shi ST et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet 2014; 46: 573–582.

  7. 7

    Ivanova T, Zouridis H, Wu Y, Cheng LL, Tan IB, Gopalakrishnan V et al. Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. Gut 2013; 62: 22–33.

  8. 8

    Asada K, Nakajima T, Shimazu T, Yamamichi N, Maekita T, Yokoi C et al. Demonstration of the usefulness of epigenetic cancer risk prediction by a multicentre prospective cohort study. Gut 2015; 64: 388–396.

  9. 9

    Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R . FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist 2005; 10: 176–182.

  10. 10

    Liu J, Zhang Y, Xie YS, Wang FL, Zhang LJ, Deng T et al. 5-Aza-2'-deoxycytidine induces cytotoxicity in BGC-823 cells via DNA methyltransferase 1 and 3a independent of p53 status. Oncol Rep 2012; 28: 545–552.

  11. 11

    Qiu H, Yashiro M, Shinto O, Matsuzaki T, Hirakawa K . DNA methyltransferase inhibitor 5-aza-CdR enhances the radiosensitivity of gastric cancer cells. Cancer Sci 2009; 100: 181–188.

  12. 12

    Niwa T, Toyoda T, Tsukamoto T, Mori A, Tatematsu M, Ushijima T . Prevention of Helicobacter pylori-induced gastric cancers in gerbils by a DNA demethylating agent. Cancer Prev Res (Phila) 2013; 6: 263–270.

  13. 13

    Liu X, Wang X, Zhang J, Lam EK, Shin VY, Cheng AS et al. Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis. Oncogene 2010; 29: 442–450.

  14. 14

    Cheung KF, Lam CN, Wu K, Ng EK, Chong WW, Cheng AS et al. Characterization of the gene structure, functional significance, and clinical application of RNF180, a novel gene in gastric cancer. Cancer 2012; 118: 947–959.

  15. 15

    Li X, Cheung KF, Ma X, Tian L, Zhao J, Go MY et al. Epigenetic inactivation of paired box gene 5, a novel tumor suppressor gene, through direct upregulation of p53 is associated with prognosis in gastric cancer patients. Oncogene 2012; 31: 3419–3430.

  16. 16

    Cheng AS, Li MS, Kang W, Cheng VY, Chou JL, Lau SS et al. Helicobacter pylori causes epigenetic dysregulation of FOXD3 to promote gastric carcinogenesis. Gastroenterology 2013; 144: 122–133 e129.

  17. 17

    Schmid CA, Muller A . FoxD3 is a novel, epigenetically regulated tumor suppressor in gastric carcinogenesis. Gastroenterology 2013; 144: 22–25.

  18. 18

    Lee SJ . Identification of a novel member (GDF-1) of the transforming growth factor-beta superfamily. Mol Endocrinol 1990; 4: 1034–1040.

  19. 19

    Burt DW, Law AS . Evolution of the transforming growth factor-beta superfamily. Prog Growth Factor Res 1994; 5: 99–118.

  20. 20

    Drabsch Y, ten Dijke P . TGF-beta signalling and its role in cancer progression and metastasis. Cancer Metast Rev 2012; 31: 553–568.

  21. 21

    Zhang L, Zhou F, ten Dijke P . Signaling interplay between transforming growth factor-beta receptor and PI3K/AKT pathways in cancer. Trends Biochem Sci 2013; 38: 612–620.

  22. 22

    Blaser MJ, Atherton JC . Helicobacter pylori persistence: biology and disease. J Clin Invest 2004; 113: 321–333.

  23. 23

    Kang W, Tong JH, Chan AW, Lung RW, Chau SL, Wong QW et al. Stathmin1 plays oncogenic role and is a target of microRNA-223 in gastric cancer. PLoS One 2012; 7: e33919.

  24. 24

    Leung WK, Wu KC, Wong CY, Cheng AS, Ching AK, Chan AW et al. Transgenic cyclooxygenase-2 expression and high salt enhanced susceptibility to chemical-induced gastric cancer development in mice. Carcinogenesis 2008; 29: 1648–1654.

  25. 25

    Shin VY, Jin H, Ng EK, Cheng AS, Chong WW, Wong CY et al. NF-kappaB targets miR-16 and miR-21 in gastric cancer: involvement of prostaglandin E receptors. Carcinogenesis 2011; 32: 240–245.

  26. 26

    Cancer Genome Atlas Research Network.. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513: 202–209.

  27. 27

    Holbrook JD, Parker JS, Gallagher KT, Halsey WS, Hughes AM, Weigman VJ et al. Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine. J Transl Med 2011; 9: 119.

  28. 28

    Nagarajan N, Bertrand D, Hillmer AM, Zang ZJ, Yao F, Jacques PE et al. Whole-genome reconstruction and mutational signatures in gastric cancer. Genome Biol 2012; 13: R115.

  29. 29

    Wang K, Kan J, Yuen ST, Shi ST, Chu KM, Law S et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet 2011; 43: 1219–1223.

  30. 30

    Zang ZJ, Cutcutache I, Poon SL, Zhang SL, McPherson JR, Tao J et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 2012; 44: 570–574.

  31. 31

    Lee SJ . Expression of growth/differentiation factor 1 in the nervous system: conservation of a bicistronic structure. Proc Natl Acad Sci USA 1991; 88: 4250–4254.

  32. 32

    Rankin CT, Bunton T, Lawler AM, Lee SJ . Regulation of left-right patterning in mice by growth/differentiation factor-1. Nat Genet 2000; 24: 262–265.

  33. 33

    Wall NA, Craig EJ, Labosky PA, Kessler DS . Mesendoderm induction and reversal of left-right pattern by mouse Gdf1, a Vg1-related gene. Dev Biol 2000; 227: 495–509.

  34. 34

    Andersson O, Reissmann E, Jornvall H, Ibanez CF . Synergistic interaction between Gdf1 and Nodal during anterior axis development. Dev Biol 2006; 293: 370–381.

  35. 35

    Cheng SK, Olale F, Bennett JT, Brivanlou AH, Schier AF . EGF-CFC proteins are essential coreceptors for the TGF-beta signals Vg1 and GDF1. Genes Dev 2003; 17: 31–36.

  36. 36

    Fuerer C, Nostro MC, Constam DB . Nodal-Gdf1 heterodimers with bound prodomains enable serum-independent nodal signaling and endoderm differentiation. J Biol Chem 2014; 289: 17854–17871.

  37. 37

    Karkera JD, Lee JS, Roessler E, Banerjee-Basu S, Ouspenskaia MV, Mez J et al. Loss-of-function mutations in growth differentiation factor-1 (GDF1) are associated with congenital heart defects in humans. Am J Hum Genet 2007; 81: 987–994.

  38. 38

    Zhang Y, Zhang XF, Gao L, Liu Y, Jiang DS, Chen K et al. Growth/differentiation factor 1 alleviates pressure overload-induced cardiac hypertrophy and dysfunction. Biochim Biophys Acta 2014; 1842: 232–244.

  39. 39

    Kaasinen E, Aittomaki K, Eronen M, Vahteristo P, Karhu A, Mecklin JP et al. Recessively inherited right atrial isomerism caused by mutations in growth/differentiation factor 1 (GDF1). Hum Mol Genet 2010; 19: 2747–2753.

  40. 40

    Sun X, Meng Y, You T, Li P, Wu H, Yu M et al. Association of growth/differentiation factor 1 gene polymorphisms with the risk of congenital heart disease in the Chinese Han population. Mol Biol Rep 2013; 40: 1291–1299.

  41. 41

    Massague J . TGFbeta signalling in context. Nat Rev Mol Cell Biol 2012; 13: 616–630.

  42. 42

    Hanahan D, Weinberg RA . The hallmarks of cancer. Cell 2000; 100: 57–70.

  43. 43

    Ehata S, Johansson E, Katayama R, Koike S, Watanabe A, Hoshino Y et al. Transforming growth factor-beta decreases the cancer-initiating cell population within diffuse-type gastric carcinoma cells. Oncogene 2011; 30: 1693–1705.

  44. 44

    Katsuno Y, Ehata S, Yashiro M, Yanagihara K, Hirakawa K, Miyazono K . Coordinated expression of REG4 and aldehyde dehydrogenase 1 regulating tumourigenic capacity of diffuse-type gastric carcinoma-initiating cells is inhibited by TGF-beta. J Pathol 2012; 228: 391–404.

  45. 45

    Leung WK, Lin SR, Ching JY, To KF, Ng EK, Chan FK et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 2004; 53: 1244–1249.

  46. 46

    Sung JJ, Lin SR, Ching JY, Zhou LY, To KF, Wang RT et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology 2000; 119: 7–14.

  47. 47

    Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004; 291: 187–194.

  48. 48

    Azad N, Zahnow CA, Rudin CM, Baylin SB . The future of epigenetic therapy in solid tumours—lessons from the past. Nat Rev Clin Oncol 2013; 10: 256–266.

  49. 49

    Geutjes EJ, Bajpe PK, Bernards R . Targeting the epigenome for treatment of cancer. Oncogene 2012; 31: 3827–3844.

  50. 50

    Feng H, Cheng AS, Tsang DP, Li MS, Go MY, Cheung YS et al. Cell cycle-related kinase is a direct androgen receptor-regulated gene that drives beta-catenin/T cell factor-dependent hepatocarcinogenesis. J Clin Invest 2011; 121: 3159–3175.

Download references

Acknowledgements

This study was supported by the Health and Medical Research Fund (08070172), National Natural Science Foundation of China (373492, 81302167), Focused Investment Scheme -Scheme B (1907301) and the Direct Grant from the Chinese University of Hong Kong.

Author information

Correspondence to A S L Cheng.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Yang, W., Mok, M., Li, M. et al. Epigenetic silencing of GDF1 disrupts SMAD signaling to reinforce gastric cancer development. Oncogene 35, 2133–2144 (2016) doi:10.1038/onc.2015.276

Download citation

Further reading